{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:53:46Z","timestamp":1787230426379,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010090","name":"Women and Children's Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012688","name":"North American Society for Pediatric Gastroenterology, Hepatology and Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10620-022-07783-3","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:04:07Z","timestamp":1671789847000},"page":"1995-2005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Early Infliximab Clearance Predicts Remission in Children with Crohn\u2019s Disease"],"prefix":"10.1007","volume":"68","author":[{"given":"Aaron","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Wine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-7308","authenticated-orcid":false,"given":"Hien","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"7783_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1572-0241.2003.07343.x","volume":"98","author":"R Baldassano","year":"2003","unstructured":"Baldassano R, Braegger CP, Escher JC et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn\u2019s disease. Am J Gastroenterol. 2003;98:833\u2013838.","journal-title":"Am J Gastroenterol."},{"key":"7783_CR2","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/MPG.0000000000000533","volume":"59","author":"JR Kelsen","year":"2014","unstructured":"Kelsen JR, Grossman AB, Pauly-Hubbard H et al. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr. 2014;59:758\u2013762.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"7783_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M et al. Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946\u2013964.","journal-title":"Clin Ther."},{"key":"7783_CR4","first-page":"48","volume":"11","author":"N Singh","year":"2015","unstructured":"Singh N, Dubinsky MC. Therapeutic drug monitoring in children and young adults with inflammatory bowel disease: a practical approach. Gastroenterol Hepatol (N Y). 2015;11:48\u201355.","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"7783_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","volume":"57","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Vande CN. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57:929\u2013942.","journal-title":"Clin Pharmacokinet."},{"key":"7783_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/ibd\/izab285","volume":"28","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Mendiolaza ML, Phan BL et al. Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity. Inflamm Bowel Dis. 2022;28:285.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1208\/s12248-016-9994-y","volume":"19","author":"MC Dubinsky","year":"2017","unstructured":"Dubinsky MC, Phan BL, Singh N et al. Pharmacokinetic dashboard-recommended dosing is different than standard of care dosing in infliximab-treated pediatric IBD patients. AAPS J. 2017;19:215\u2013222.","journal-title":"AAPS J."},{"key":"7783_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00228-020-02975-0","volume":"77","author":"MB Dave","year":"2021","unstructured":"Dave MB, Dherai AJ, Desai DC et al. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience. Eur J Clin Pharmacol. 2021;77:55\u201362.","journal-title":"Eur J Clin Pharmacol."},{"key":"7783_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ibd\/izz143","volume":"26","author":"LE Bauman","year":"2020","unstructured":"Bauman LE, Xiong Y, Mizuno T et al. Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2020;26:429\u2013439.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/MPG.0000000000001620","volume":"65","author":"A Frymoyer","year":"2017","unstructured":"Frymoyer A, Hoekman DR, Piester TL et al. Application of population pharmacokinetic modeling for individualized infliximab dosing strategies in Crohn disease. J Pediatr Gastroenterol Nutr. 2017;65:639\u2013645.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"7783_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","volume":"15","author":"K Papamichael","year":"2017","unstructured":"Papamichael K, Chachu KA, Vajravelu RK et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15:1580\u20131588.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7783_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/ibd\/izaa102","volume":"27","author":"JL Lyles","year":"2021","unstructured":"Lyles JL, Mulgund AA, Bauman LE et al. Effect of a practice-wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:482\u2013492.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR13","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","volume":"20","author":"BP Vaughn","year":"2014","unstructured":"Vaughn BP, Martinez-Vazquez M, Patwardhan VR et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20:1996\u20132003.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/MPG.0000000000002440","volume":"69","author":"RZ Cohen","year":"2019","unstructured":"Cohen RZ, Schoen BT, Kugathasan S et al. Management of anti-drug antibodies to biologic medications in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;69:551\u2013556.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"7783_CR15","doi-asserted-by":"publisher","first-page":"3762651","DOI":"10.1155\/2017\/3762651","volume":"2017","author":"I Unal","year":"2017","unstructured":"Unal I. Defining an optimal cut-point value in ROC analysis: an alternative approach. Comput Math Methods Med. 2017;2017:3762651.","journal-title":"Comput Math Methods Med."},{"key":"7783_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/psp4.12385","volume":"8","author":"Q Wu","year":"2019","unstructured":"Wu Q, Peters SA. A retrospective evaluation of allometry, population pharmacokinetics, and physiologically-based pharmacokinetics for pediatric dosing using clearance as a surrogate. CPT Pharmacometrics Syst Pharmacol. 2019;8:220\u2013229.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"7783_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/psp4.12456","volume":"8","author":"PRV Malik","year":"2019","unstructured":"Malik PRV, Edginton AN. Physiologically-based pharmacokinetic modeling vs. allometric scaling for the prediction of infliximab pharmacokinetics in pediatric patients. CPT Pharmacometrics Syst Pharmacol. 2019;8:835\u2013844.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"7783_CR18","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/ibd\/izy129","volume":"24","author":"A Petitcollin","year":"2018","unstructured":"Petitcollin A, Leuret O, Tron C et al. Modeling immunization to infliximab in children with Crohn\u2019s disease using population pharmacokinetics: a pilot study. Inflamm Bowel Dis. 2018;24:1745\u20131754.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR19","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","volume":"20","author":"N Singh","year":"2014","unstructured":"Singh N, Rosenthal CJ, Melmed GY et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1708\u20131713.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/MIB.0000000000000284","volume":"21","author":"NL Zitomersky","year":"2015","unstructured":"Zitomersky NL, Atkinson BJ, Fournier K et al. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis. 2015;21:307\u2013314.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ibd\/izaa108","volume":"27","author":"RJ Colman","year":"2021","unstructured":"Colman RJ, Portocarrero-Castillo A, Chona D et al. Favorable outcomes and anti-TNF durability after addition of an immunomodulator for anti-drug antibodies in pediatric IBD patients. Inflamm Bowel Dis. 2021;27:507\u2013515.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR22","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.cgh.2015.04.010","volume":"13","author":"V Grossi","year":"2015","unstructured":"Grossi V, Lerer T, Griffiths A et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13:1748\u20131756.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7783_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/MPG.0000000000002051","volume":"67","author":"B Ungar","year":"2018","unstructured":"Ungar B, Glidai Y, Yavzori M et al. Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2018;67:507\u2013512.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"7783_CR24","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","volume":"63","author":"F Cornillie","year":"2014","unstructured":"Cornillie F, Hanauer SB, Diamond RH et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63:1721\u20131727.","journal-title":"Gut."},{"key":"7783_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/MPG.0000000000001302","volume":"64","author":"T Hofmekler","year":"2017","unstructured":"Hofmekler T, Bertha M, McCracken C et al. Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64:580\u2013585.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"7783_CR26","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/MIB.0000000000000769","volume":"22","author":"R Stein","year":"2016","unstructured":"Stein R, Lee D, Leonard MB et al. Serum infliximab, antidrug antibodies, and tumor necrosis factor predict sustained response in pediatric Crohn\u2019s disease. Inflamm Bowel Dis. 2016;22:1370\u20131377.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1208\/s12248-018-0257-y","volume":"20","author":"AS Strik","year":"2018","unstructured":"Strik AS, Wang YC, Ruff LE et al. Individualized dosing of therapeutic monoclonal antibodies-a changing treatment paradigm? AAPS J. 2018;20:99.","journal-title":"AAPS J."},{"key":"7783_CR28","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","volume":"20","author":"I Dotan","year":"2014","unstructured":"Dotan I, Ron Y, Yanai H et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20:2247\u20132259.","journal-title":"Inflamm Bowel Dis."},{"key":"7783_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MPG.0000000000002536","volume":"70","author":"O Courbette","year":"2020","unstructured":"Courbette O, Aupiais C, Viala J et al. Trough levels of infliximab at week 6 are predictive of remission at week 14 in pediatric Crohn\u2019s disease. J Pediatr Gastroenterol Nutr. 2020;70:310\u2013317.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"7783_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827\u2013834.","journal-title":"Gastroenterology."},{"key":"7783_CR31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","volume":"46","author":"N Mitrev","year":"2017","unstructured":"Mitrev N, Vande Casteele N, Seow CH et al. Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46:1037\u20131053.","journal-title":"Aliment Pharmacol Ther."},{"key":"7783_CR32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"N Vande Casteele","year":"2015","unstructured":"Vande Casteele N, Ferrante M, Van Assche G et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320\u20131329.","journal-title":"Gastroenterology."},{"key":"7783_CR33","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/apt.13757","volume":"44","author":"J Afonso","year":"2016","unstructured":"Afonso J, Lopes S, Gon\u00e7alves R et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016;44:684\u2013692.","journal-title":"Aliment Pharmacol Ther."},{"key":"7783_CR34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","volume":"70","author":"DA Winter","year":"2020","unstructured":"Winter DA, Joosse ME, de Wildt SN et al. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. J Pediatr Gastroenterol Nutr. 2020;70:763\u2013776.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"7783_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","volume":"19","author":"E Louis","year":"2004","unstructured":"Louis E, El Ghoul Z, Vermeire S et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn\u2019s disease. Aliment Pharmacol Ther. 2004;19:511\u2013519.","journal-title":"Aliment Pharmacol Ther."},{"key":"7783_CR36","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/ajg.2016.306","volume":"111","author":"T Billiet","year":"2016","unstructured":"Billiet T, Dreesen E, Cleynen I et al. A genetic variation in the neonatal Fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease. Am J Gastroenterol. 2016;111:1438\u20131445.","journal-title":"Am J Gastroenterol."},{"key":"7783_CR37","first-page":"1386","volume":"21","author":"G Zubin","year":"2015","unstructured":"Zubin G, Peter L. Predicting endoscopic Crohn\u2019s disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and Fecal Calprotectin. Inflamm Bowel Dis. 2015;21:1386\u20131391.","journal-title":"Inflamm Bowel Dis."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07783-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07783-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07783-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T04:20:43Z","timestamp":1682482843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07783-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7783"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07783-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"16 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hien Q Huynh has received educational grants from AbbVie and Janssen and served as an advisory board member for BioJamp. He has also received speaker fees from AbbVie, Janssen and Fresenius. Eytan Wine has received speaker fees from AbbVie, Janssen, Nestle Health Sciences, BioJamp, Pfizer, and Mead Johnson Nutrition. Matthew W Carroll has received speaker fees from AbbVie. Diane R Mould is the president of Projections Research Inc, a consulting company for the pharmaceutical industry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}